A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GalNAc-hexyl-threoninol-CPG | GalNAc-hexyl-threoninol-CPG is a solid-supported GalNAc (N-acetylgalactosamine) monomer designed for the efficient synthesis of GalNAc-conjugated oligonucleotides. It features a GalNAc moiety attached to a threoninol scaffold via a hexyl linker, with the primary hydroxyl group protected by a dimethoxytrityl (DMT) group. The compound is immobilized on a solid support (controlled-pore glass, CPG) through a succinylated linker, facilitating its use in solid-phase synthesis. This configuration allows for the convenient and scalable incorporation of GalNAc units into oligonucleotides, enhancing their targeting efficiency to hepatocytes via the asialoglycoprotein receptor (ASGPR). GalNAc-hexyl-threoninol-CPG serves as a versatile building block for developing targeted nucleic acid therapeutics with improved cellular uptake and specificity. |  |
| GalNAc-L96-Amide | GalNAc-L96-Amide is a specialized compound within the GalNAc series, designed for targeted delivery of nucleic acid drugs to hepatocytes. This molecule features a triantennary GalNAc (N-acetylgalactosamine) core linked to a longer PEG-based linker and terminated with an amide group. The GalNAc core serves as a high-affinity ligand for the asialoglycoprotein receptor (ASGPR), which is highly expressed on hepatocytes, enabling efficient liver-targeted delivery. The compound is used primarily for the synthesis of GalNAc-siRNA conjugates, which leverage the ASGPR pathway to enhance the uptake and efficacy of siRNA molecules in the liver. This targeted delivery system avoids the immunogenicity associated with lipid-based delivery methods and improves the safety and specificity of nucleic acid therapies. GalNAc-L96-Amide is also a key intermediate in the development of advanced drug delivery systems, particularly for RNA interference (RNAi) therapies. Grade: >98%. | |
| GalNac-L96 analog | GalNAc-L96 analog is an intermediate used in the synthesis of ligands targeting the asialoglycoprotein receptor (ASGPR), a receptor highly expressed on hepatocytes and involved in the internalization and degradation of desialylated glycoproteins. It features a triantennary GalNAc (N-acetylgalactosamine) structure designed to enhance the targeting and delivery of nucleic acid drugs to liver cells. It is commonly used in the development of GalNAc-siRNA conjugates, which leverage the high affinity of GalNAc for ASGPR to facilitate efficient cellular uptake and endosomal release of siRNA molecules, thereby improving the efficacy of RNA-based therapies. Synonyms: N-Acetylgalactosamine-L96 analog; GalNAc-L96; N-acetyl-D-Galactosamine-L96 analog; (2S,4R)-2-[[Bis(4-methoxyphenyl)phenylmethoxy]methyl]-4-hydroxy-λ-oxo-N-[2-[3-oxo-3-[[3-[[1-oxo-5-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]pentyl]amino]propyl]amino]propoxy]-1,1-bis[[3-oxo-3-[[3-[[1-oxo-5-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]pentyl]amino]propyl]amino]propoxy]methyl]ethyl]-1-pyrrolidinedodecanamide. Grade: ≥95%. CAS No. 1159408-72-6. Molecular formula: C117H175N11O42. Mole weight: 2407.69. | |
| GalNAc-L96-CPG | GalNAc-L96-CPG is a solid support reagent designed for the synthesis of GalNAc-conjugated oligonucleotides, particularly siRNA, for targeted delivery applications. It consists of a triantennary GalNAc ligand (specifically the L96 variant) covalently attached to a controlled pore glass (CPG) support via a linker. The GalNAc moiety serves as a high-affinity ligand for the asialoglycoprotein receptor (ASGPR), which is abundantly expressed on hepatocytes, enabling efficient receptor-mediated endocytosis of the conjugated oligonucleotide into liver cells. This system facilitates the development of RNA interference (RNAi) therapeutics, such as GalNAc-siRNA conjugates, by enhancing cellular uptake and pharmacokinetic properties. Synonyms: 3'-GalNAc CPG 1000; GalNAc-L96 CPG. | |
| GalNac-L96 free base | GalNAC-L96 free base is a triantennary GalNAc ligand that can be used for the synthesis of GalNAC-SiRNA and for the delivery of nucleic acid drugs. GalNAc is a ligand for the asialal glycoprotein receptor (ASGPR). Synonyms: L-96; Butanedioic acid, 1-[(3R,5S)-5-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-1-[1,12,19,25-tetraoxo-14,14-bis[[3-oxo-3-[[3-[[1-oxo-5-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]pentyl]amino]propyl]amino]propoxy]methyl]-29-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-16-oxa-13,20,24-triazanonacos-1-yl]-3-pyrrolidinyl] ester; 1-[(3R,5S)-5-[[Bis(4-methoxyphenyl)phenylmethoxy]methyl]-1-[1,12,19,25-tetraoxo-14,14-bis[[3-oxo-3-[[3-[[1-oxo-5-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]pentyl]amino]propyl]amino]propoxy]methyl]-29-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-16-oxa-13,20,24-triazanonacos-1-yl]-3-pyrrolidinyl] butanedioate; GalNAc-L96-SA; L-96-Succinic Acid; GalNAc-L96-Succinate. Grade: 98%. CAS No. 1159408-61-3. Molecular formula: C121H179N11O45. Mole weight: 2507.76. | |
| GalNAc-L96 Linker-Acid | GalNAc-L96 Linker-Acid is a specialized chemical compound designed for the synthesis of targeted nucleic acid delivery systems. It features a triantennary GalNAc (N-acetylgalactosamine) cluster linked to a longer PEG-based linker, terminating with a carboxylic acid group. This structure allows for efficient conjugation to oligonucleotides, such as siRNA, enabling targeted delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR). The compound is widely used in the development of RNA interference (RNAi) therapies, particularly for liver-related diseases. This linker is a key intermediate in the synthesis of GalNAc-siRNA conjugates, which have demonstrated superior stability and gene silencing efficiency compared to traditional lipid nanoparticle delivery systems. Synonyms: 12,19,25-Trioxo-14,14-bis[[3-oxo-3-[[3-[[1-oxo-5-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]pentyl]amino]propyl]amino]propoxy]methyl]-29-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-16-oxa-13,20,24-triazanonacosanoic acid; 1-(((2R,3R,4R,5R,6R)-3-Acetamido-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-16,16-bis((3-((3-(5-(((2R,3R,4. Grade: ≥97%. CAS No. 1426159-34-3. Molecular formula: C91H148N10O39. Mole weight: 2006.22. | |
| GalNAc-L96 Linker-Azide | GalNAc-L96 Linker-Azide is a specialized chemical compound designed for the development of targeted nucleic acid delivery systems. It features a triantennary GalNAc (N-acetylgalactosamine) cluster linked to a PEG-based linker, terminating with an azide group. This structure allows for efficient conjugation to oligonucleotides or other therapeutic agents through click chemistry, enabling targeted delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR). GalNAc-L96 Linker-Azide is particularly useful in the synthesis of GalNAc-siRNA conjugates, which have demonstrated high efficiency in liver-targeted gene silencing. The azide group provides a convenient handle for conjugation, making it suitable for the development of advanced drug delivery systems, especially for RNA interference (RNAi) therapies. Grade: ≥97%. CAS No. 2135330-72-0. Molecular formula: C90H147N13O37. Mole weight: 2003.22. | |
| GalNAc-Lipid GL3 | GalNAc-Lipid GL3 is a first-generation GalNAc-based ligand designed for targeted delivery of therapeutic agents to hepatocytes via the asialoglycoprotein receptor (ASGPR). It features a trivalent GalNAc structure attached to a TRIS scaffold, which facilitates efficient binding to ASGPR and subsequent cellular uptake. In preclinical studies, GalNAc-Lipid GL3 was formulated into lipid nanoparticles (LNPs) and tested for its ability to deliver CRISPR base editors to the liver. While effective, GL3 demonstrated lower editing efficiency compared to its second-generation counterpart, GalNAc-Lipid GL6, which achieved higher liver editing rates in both LDLR-deficient and wild-type mice. This suggests that GL3's TRIS scaffold may be less optimal than the lysine-based scaffold used in GL6 for ASGPR-mediated uptake and delivery. Despite this, GalNAc-Lipid GL3 remains an important reference in the development of targeted liver delivery systems, highlighting the potential of GalNAc ligands for non-LDLR-dependent therapies. Grade: >98%. | |
| GalNAc-Lipid GL5 | GalNAc-Lipid GL5 is a targeting ligand designed for lipid nanoparticles (LNPs) with a short 12-unit PEG linker. It enables non-LDLR (low-density lipoprotein receptor)-dependent delivery of therapeutic agents to hepatocytes. However, compared to GL6 with a longer PEG linker, GL5 exhibits lower liver-targeting efficiency. For instance, in experiments targeting the _Angptl3_ gene in mice, GL5 achieved only 18% liver editing efficiency, while GL6 reached 56%. This suggests that the shorter PEG linker in GL5 may limit its binding affinity to ASGPR (asialoglycoprotein receptor) on hepatocytes. Despite its lower efficiency, GL5 remains valuable for understanding the structure-function relationship in GalNAc-LNP design. Grade: ≥98%. | |
| GalNAc-Lipid GL6 | GalNAc-Lipid GL6 is a potent and scalable ligand designed for targeted liver delivery of therapeutic agents, particularly in the context of CRISPR base editing therapies. It features a multi-valent N-acetylgalactosamine (GalNAc) structure that binds specifically to the asialoglycoprotein receptor (ASGPR), enabling efficient uptake by hepatocytes. This ligand is part of the second-generation GalNAc design, which incorporates a lysine-based scaffold and a longer PEG spacer (34-38 units) compared to earlier designs. The combination of a 1,2-O-dioctadecyl-sn-glyceryl (DSG) lipid anchor and the optimized PEG spacer enhances the stability and delivery efficiency of lipid nanoparticles (LNPs) in vivo. In preclinical studies, GalNAc-Lipid GL6 demonstrated superior performance in liver-targeted gene editing compared to other GalNAc ligands, achieving high editing rates in both wild-type and LDLR-deficient mice and non-human primates. This ligand has shown significant potential for non-LDLR-dependent delivery of CRISPR therapies, making it a valuable tool for treating genetic disorders and metabolic diseases. Grade: 98%. | |
| GalNAc-Lipid GL7 | GalNAc-Lipid GL7 is a ligand designed to optimize the delivery of lipid nanoparticles (LNPs) to hepatocytes via non-LDLR (low-density lipoprotein receptor) dependent pathways. It is based on Design 2, which features a lysine scaffold with three GalNAc units attached through a 36-unit PEG linker. The primary goal of GL7 is to evaluate the impact of different lipid anchors on the stability and delivery efficiency of LNPs. Specifically, GL7 incorporates a cholesteryl (Chol) lipid anchor, which was tested alongside other lipid anchors like 1,2-O-dioctadecyl-sn-glyceryl (DSG) and arachidoyl (C20) to assess their effects on ASGPR (asialoglycoprotein receptor) recognition and binding. However, experiments in Ldlr-mice demonstrated that the DSG lipid anchor in GL6 was significantly more effective for liver-targeted gene editing compared to the cholesterol anchor in GL7, with an editing efficiency of 56% for DSG versus 4% for cholesterol. This suggests that GL7, with its cholesterol anchor, is less efficient for non-LDLR-dependent delivery of LNPs to hepatocytes. Grade: ≥98%. | |
| GalNAc-Lipid GL9 | GalNAc-Lipid GL9 is a ligand designed for lipid nanoparticles (LNPs) to facilitate non-LDLR (low-density lipoprotein receptor)-dependent delivery of therapeutic agents to hepatocytes. It is based on Design 2, which uses a lysine scaffold with three GalNAc units attached through a PEG linker. The primary goal of GL9 is to evaluate the impact of different lipid anchors on the stability and delivery efficiency of LNPs. In GL9, the lipid anchor is an arachidoyl (C20) moiety, which was tested alongside other lipid anchors like 1,2-O-dioctadecyl-sn-glyceryl (DSG) and cholesterol (Chol) to assess their effects on ASGPR (asialoglycoprotein receptor) recognition and binding. However, experiments in LDLR-deficient mice demonstrated that the DSG lipid anchor in GL6 was significantly more effective for liver-targeted gene editing compared to the arachidoyl (C20) anchor in GL9. Specifically, the editing efficiency of GL6 with DSG was 56%, while GL9 with C20 achieved only 8% efficiency. This indicates that GL9, with its C20 lipid anchor, is less efficient for non-LDLR-dependent delivery of LNPs to hepatocytes. Grade: ≥98%. | |
| GalNAc-NAG-25 Phosphoramidite | GalNAc-NAG-25 Phosphoramidite is a modified phosphoramidite that incorporates a N-acetylgalactosamine (GalNAc) moiety linked to the NAG component, specifically designed for the synthesis of oligonucleotides. This compound enhances the stability and bioactivity of nucleic acids, particularly in applications involving targeted delivery and therapeutic interventions. Its unique structural features allow for improved interactions with cellular receptors, making GalNAc-NAG-25 Phosphoramidite valuable in the development of glyco-engineered therapeutics and in the field of glycobiology, where carbohydrate-based modifications play a crucial role in biological processes. Synonyms: NAG-25; NAG 25; NAG25; GalNAc NAG-25 Phosphoramidite; N2-[23-[Bis(1-methylethyl)amino]-26-cyano-1-oxo-4,7,10,13,16,19,22,24-octaoxa-23-phosphahexacos-1-yl]-N-[2-[2-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethyl]-L-γ-glutamyl-N,N2-bis[2-[2-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethyl]-L-glutamamide. Grade: ≥95%. CAS No. 2130036-52-9. Molecular formula: C88H145N10O43P. Mole weight: 2062.13. | |
| GalNAc-PEG-Cluster-1-CPG | GalNAc-PEG-Cluster-1-CPG is a specialized reagent used for the synthesis of oligonucleotide conjugates, particularly for liver-targeted drug delivery. It combines N-acetylgalactosamine (GalNAc) with a polyethylene glycol (PEG) linker and a controlled pore glass (CPG) support to facilitate the attachment of GalNAc clusters to oligonucleotides. This structure enhances the targeting of siRNA or other nucleic acid drugs to hepatocytes via the asialoglycoprotein receptor (ASGPR), improving cellular uptake and therapeutic efficacy. Grade: ≥98%. | |
| Galnon | Galnon is a non-peptide galanin GAL1 and GAL2 receptor agonist (Ki = 11.7 and 34.1 μM, respectively) with anticonvulsant, anxiolytic, anorectic and amnestic activities. It stimulates insulin release in isolated pancreatic islets from normal and diabetic rats. Synonyms: 3-Cyclohexyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-L-lysinamide; L-Lysinamide, 3-cyclohexyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-; Fmoc-b-cyclohexyl-Ala-Lys-AMC. Grade: ≥95% by HPLC. CAS No. 475115-35-6. Molecular formula: C40H46N4O6. Mole weight: 678.83. | |
| Galnon | Galnon. Group: Biochemicals. Grades: Purified. CAS No. 475115-35-6. Pack Sizes: 10mg. US Biological Life Sciences. |  Worldwide |
| Galnon TFA | Galnon is a non-peptide galanin GAL1 and GAL2 receptor agonist (Ki = 11.7 and 34.1 μM, respectively) with anticonvulsant, anxiolytic, anorectic and amnestic activities. It stimulates insulin release in isolated pancreatic islets from normal and diabetic rats. Synonyms: L-Lysinamide, 3-cyclohexyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-, 2,2,2-trifluoroacetate (1:1); Fmoc-Cha-Lys-AMC.TFA; 3-Cyclohexyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-L-lysinamide trifluoroacetate salt; Galnon trifluoroacetate salt; Galnon Trifluoroacetate. Grade: ≥95%. CAS No. 1217448-19-5. Molecular formula: C40H46N4O6.C2HF3O2. Mole weight: 792.84. | |
| Galpα1,3-[U-13C6]Galpβ1,4GlcNAcitol | Galpα1,3-[U-13C6]Galpβ1,4GlcNAcitol. Synonyms: Galp-alpha-1,3-[UL-13C6]Galp-beta-1,4-GlcNAcitol; Galp-a3-[U-13C6]Galp-b4-GlcNAcitol; Gal(a3)[UL-13C6]Gal(b4)GlcNAcitol. Molecular formula: C14[13C]6H37NO16. Mole weight: 553.46. | |
| Galpα1,3-[U-13C6]Galpβ1,4GlcpNAc | Galpα1,3-[U-13C6]Galpβ1,4GlcpNAc. Synonyms: Galp-alpha-1,3-[UL-13C6]Galp-beta-1,4-GlcpNAc; Galp-a3-[U-13C6]Galp-b4-GlcNAc; Gal(a3)[UL-13C6]Gal(b4)GlcNAc. Molecular formula: C14[13C]6H35NO16. Mole weight: 551.44. | |
| Galpα1,3-[U-13C6]Galpβ1,4GlcpNAcα1-O-Bn | Galpα1,3-[U-13C6]Galpβ1,4GlcpNAcα1-O-Bn. Synonyms: Galp-alpha-1,3-[UL-13C6]Galp-beta-1,4-GlcpNAc-alpha-1-O-Bn; Galp-a3-[UL-13C6]Galp-b4-GlcNAc-a1-O-Bn; Gal(a3)[U-13C6]Gal(b4)GlcNAc-a1-O-Bn. Molecular formula: C21[13C]6H41NO16. Mole weight: 641.57. | |
| Galpβ1,2Galpβ1,6([U-13C6]Galfβ1,4)GlcNAcitol | Galpβ1,2Galpβ1,6([U-13C6]Galfβ1,4)GlcNAcitol. Synonyms: Galp-beta-1,2-Galp-beta-1,6-(UL-13C6-Galf-beta-1,4)-GlcNAcitol; Galp(b2)Galp(b6)[UL-13C6-Galf(b4)]GlcNAcitol. Molecular formula: C20[13C]6H47NO21. Mole weight: 715.60. | |
| Galpβ1,2Galpβ1,6([U-13C6]Galfβ1,4)GlcpNAc | Galpβ1,2Galpβ1,6([U-13C6]Galfβ1,4)GlcpNAc. Synonyms: Galp-beta-1,2-Galp-beta-1,6-(UL-13C6-Galf-beta-1,4)-GlcpNAc; Galp(b2)Galp(b6)[UL-13C6-Galf(b4)]GlcNAc. Molecular formula: C20[13C]6H45NO21. Mole weight: 713.58. | |
| Galpβ1,2Galpβ1,6([U-13C6]Galpβ1,3)GlcNAcitol | Galpβ1,2Galpβ1,6([U-13C6]Galpβ1,3)GlcNAcitol. Synonyms: Galp-beta-1,2-Galp-beta-1,6-(UL-13C6-Galp-beta-1,3)-GlcNAcitol; Galp(b2)Galp(b6)[UL-13C6-Galp(b3)]GlcNAcitol. Molecular formula: C20[13C]6H47NO21. Mole weight: 715.60. | |
| Galpβ1,2Galpβ1,6([U-13C6]Galpβ1,4)GlcNAcitol | Galpβ1,2Galpβ1,6([U-13C6]Galpβ1,4)GlcNAcitol. Synonyms: Galp-beta-1,2-Galp-beta-1,6-(UL-13C6-Galp-beta-1,4)-GlcNAcitol; Galp(b2)Galp(b6)[UL-13C6-Galp(b4)]GlcNAcitol. Molecular formula: C20[13C]6H47NO21. Mole weight: 715.60. | |
| Galpβ1,2Galpβ1,6([U-13C6]Galpβ1,4)GlcpNAc | Galpβ1,2Galpβ1,6([U-13C6]Galpβ1,4)GlcpNAc. Synonyms: Galp-beta-1,2-Galp-beta-1,6-(UL-13C6-Galp-beta-1,4)-GlcpNAc; Galp(b2)Galp(b6)[UL-13C6-Galp(b4)]GlcNAc. Molecular formula: C20[13C]6H45NO21. Mole weight: 713.58. | |
| Galpβ1,3Galpβ1,6([U-13C6]Galfβ1,4)GlcNAcitol | Galpβ1,3Galpβ1,6([U-13C6]Galfβ1,4)GlcNAcitol. Synonyms: Galp-beta-1,3-Galp-beta-1,6-(UL-13C6-Galf-beta-1,4)-GlcNAcitol; Galp(b3)Galp(b6)[UL-13C6-Galf(b4)]GlcNAcitol. Molecular formula: C20[13C]6H47NO21. Mole weight: 715.60. | |
| Galpβ1,3Galpβ1,6([U-13C6]Galfβ1,4)GlcpNAc | Galpβ1,3Galpβ1,6([U-13C6]Galfβ1,4)GlcpNAc. Synonyms: Galp-beta-1,3-Galp-beta-1,6-(UL-13C6-Galf-beta-1,4)-GlcpNAc; Galp(b3)Galp(b6)[UL-13C6-Galf(b4)]GlcNAc. Molecular formula: C20[13C]6H45NO21. Mole weight: 713.58. | |
| Galunisertib | Galunisertib Inhibitor. Uses: Scientific use. Product Category: T2510. CAS No. 700874-72-2. |  |
| Galunisertib | Galunisertib (LY2157299) is an oral and selective TGF-? receptor type I (TGF-?RI) kinase inhibitor with an IC50 of 56 nM. Uses: Scientific research. Group: Signaling pathways. Alternative Names: LY2157299. CAS No. 700874-72-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg; 1 g. Product ID: HY-13226. |  |
| Galunisertib | Galunisertib is a potent and selective inhibitor of transforming growth factor beta receptor (TGF-βR) kinase. It was shown to inhibit self-renewal of cancer stem cells. Synonyms: LY 2157299; LY-2157299; 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide. Grade: >98%. CAS No. 700874-72-2. Molecular formula: C22H19N5O. Mole weight: 369.428. | |
| Galvinoxyl free radical | Galvinoxyl free radical. Group: Organic radicalsbattery materials plastic additives. Alternative Names: Galvinoxylradical. CAS No. 2370-18-5. Molecular formula: 421.6. Mole weight: C29H41O2. CC (C) (C)C1=CC (=CC (=C1[O])C (C) (C)C)C=C2C=C (C (=O)C (=C2)C (C) (C)C)C (C) (C)C. InChI=1S/C29H41O2/c1-26(2, 3)20-14-18(15-21(24(20)30)27(4, 5)6)13-19-16-22(28(7, 8)9)25(31)23(17-19)29(10, 11)12/h13-17H, 1-12H3. GNZDAXRYGVFYPU-UHFFFAOYSA-N. |  |
| Gamabufotalin | Gamabufotalin. Group: Biochemicals. Alternative Names: Gamabufagin; Gamabufogenin. Grades: Plant Grade. CAS No. 465-11-2. Pack Sizes: 20mg. Molecular Formula: C24H34O5, Molecular Weight: 402.524. US Biological Life Sciences. | Worldwide |
| gama-Glu-Lys20-Liraglutide | An impurity of Liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily to treat type 2 diabetes (T2D) and obesity. Synonyms: His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(gama-Glu)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly; glutamate-Lirapeptide (synthetic); HAEGTFTSDVSSYLEGQAA-Lys(γ-Glu)-EFIAWLVRGRG; L-Histidyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-[L-γ-glutamyl]-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginylglycine; [γ-Glu-Lys20]-Liraglutide. Grade: ≥95%. CAS No. 2135342-94-6. Molecular formula: C156H235N43O50. Mole weight: 3512.85. | |
| Gama-Hydroxy Baclofen | Gama-Hydroxy Baclofen is the impurity of Baclofen, which is a specific GABA-B receptor agonist with muscle relaxant effect. Molecular formula: C10H12ClNO3. Mole weight: 229.66. | |
| Gambierol | It is produced by the strain of Gambierdiscus toxicus. Gambierol is the substance that causes ciguatera poisoning (severe diarrhea, perceptual abnormalities, etc.). Synonyms: (-)-Gambierol. Grade: 99%. CAS No. 146763-62-4. Molecular formula: C43H64O11. Mole weight: 756.96. | |
| Gambogenic Acid | Gambogenic acid is an active ingredient in gamboge, with anticancer activity. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination. Uses: Designed for use in research and industrial production. Additional or Alternative Names: (2Z)-4-[(1R,3aS,5S,12aS)-9-[(2E)-3,7-Dimethyl-2,6-octadien-1-yl]-3a,4,5,7-tetrahydro-8,10-dihydroxy-3,3-dimethyl-11-(3-methyl-2-buten-1-yl)-7,13-dioxo-1,5-methano-1H,3H-furo[3,4-d]xanthen-1-yl]-2-methyl-2-butenoic acid. Product Category: Inhibitors. Appearance: Brownish red powder. CAS No. 173932-75-7. Molecular formula: C38H46O8. Mole weight: 630.77. Purity: 0.98. IUPACName: (Z)-4-[(1S,2S,13S,15R)-7-[(2E)-3,7-dimethylocta-2,6-dienyl]-6,8-dihydroxy-17,17-dimethyl-5-(3-methylbut-2-enyl)-10,14-dioxo-3,16-dioxapentacyclo[11.4.1.02,11.02,15.04,9]octadeca-4,6,8,11-tetraen-15-yl]-2-methylbut-2-enoic acid. Canonical SMILES: CC(=CCC/C(=C/CC1=C(C(=C2C(=C1O)C(=O)C3=C[C@@H]4C[C@@H]5[C@@]3(O2)[C@](C4=O)(OC5(C)C)C/C=C(/C)\C(=O)O)CC=C(C)C)O)/C)C. Density: 1.27±0.1 g/ml. Product ID: ACM173932757. Alfa Chemistry ISO 9001:2015 Certified. |  |
| Gambogic Acid | Gambogic Acid is an apoptosis inducer in sever tumor cell lines via regulation of Bax and inhibition of Bcl-2 genes. Induces EGFR degredation through AMPK dependant-LRIG1 upregulation in glioma cells. Apoptosis inducer in several tumor cell lines including T47D cells. Activates caspases (EC50 values are 0.78 - 1.64uM) and competitively inhibits antiapoptotic Bcl-2 family proteins (IC50 values are 1.47, 1.21, 2.02, 0.66, 1.06 and 0.79uM for Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 respectively). Reverses gefitinib-resistance in mice bearing tumors with EGFR-T790M mutation. Also blocks Kir2.1 channels (EC50 ≤100nM). Group: Biochemicals. Alternative Names: (2Z)-2-Methyl-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-g]pyrano[3,2-b]xanthen-1-yl]-2-butenoic acid. Grades: Purified. CAS No. 2752-65-0. Pack Sizes: 10mg, 50mg. Molecular Formula: C38H44O8, Molecular Weight: 628.75. US Biological Life Sciences. | Worldwide |
| Gambogic Acid | Gambogic Acid (Beta-Guttiferrin) is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic Acid (Beta-Guttiferrin) inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM. Uses: Designed for use in research and industrial production. Additional or Alternative Names: β-Guttilactone. Product Category: Inhibitors. Appearance: Yellow powder. CAS No. 2752-65-0. Molecular formula: C38H44O8. Mole weight: 628.75. Purity: 0.98. IUPACName: (Z)-4-[(1S,2S,8R,17S,19R)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.02,15.02,19.04,13.06,11]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid. Canonical SMILES: CC(=CCC[C@@]1(C=CC2=C(C3=C(C(=C2O1)CC=C(C)C)O[C@@]45[C@H]6C[C@@H](C=C4C3=O)C(=O)[C@@]5(OC6(C)C)C/C=C(/C)\C(=O)O)O)C)C. Density: 1.11 g/ml. Product ID: ACM2752650. Alfa Chemistry ISO 9001:2015 Certified. | |
| Gambogic Acid | Gambogic Acid (Beta-Guttiferrin) is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic Acid (Beta-Guttiferrin) inhibits Bcl-X L , Bcl-2 , Bcl-W , Bcl-B , Bfl-1 and Mcl-1 with IC 50 s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM. Uses: Scientific research. Group: Natural products. Alternative Names: Beta-Guttiferrin. CAS No. 2752-65-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-N0087. | |
| Gambogic Acid Liposome | Gambogic acid (GA) is derived from the gamboge and is a protease activator and apoptosis inducer. This product is a pre-formulated liposome encapsulating Gambogic Acid. It is only for research purposes. Group: Drug-loaded liposome. Categories: Niosomes, ethosomes, and transfersomes. |  |
| Gambogic amide | Gambogic amide is a potent and selective agonist of TrkA and also induces its tyrosine phosphorylation and activation of downstream signaling, including Akt and MAPK. Gambogic amide specifically interacts with the cytoplasmic juxtamembrane domain of the TrkA receptor and triggers its dimerization, leading to activation. Gambogic amide has neuroprotective activity preventing glutamate-induced neuronal cell death. Gambogic amide has improved efficacy in a transient middle cerebral artery occlusion model of stroke and could be used to study neurodegenerative diseases and stroke [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 286935-60-2. Pack Sizes: 5 mg; 10 mg. Product ID: HY-121833. | |
| Gamcemetinib | Gamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM). Gamcemetinib is extracted from patent WO2020236636, compound 1[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CC-99677. CAS No. 1887069-10-4. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139504. | |
| gametolysin | A glycoprotein found in the periplasmic space of Chlamydomonas reinhardtii gametes in a 62 kDa inactive form; decreased to 60 kDa upon activation. A zinc enzyme, inhibited by phosphoramidon, but also thiol activated. Type example of peptidase family M11. Group: Enzymes. Synonyms: autolysin, Chlamydomonas cell wall degrading protease; lysin; Chlamydomonas reinhardtii metalloproteinase; gamete lytic enzyme; gamete autolysin. Enzyme Commission Number: EC 3.4.24.38. CAS No. 97089-74-2. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-4320; gametolysin; EC 3.4.24.38; 97089-74-2; autolysin, Chlamydomonas cell wall degrading protease; lysin; Chlamydomonas reinhardtii metalloproteinase; gamete lytic enzyme; gamete autolysin. Cat No: EXWM-4320. |  |
| g-Aminobutyric acid benzyl ester p-tosylate 98+% (HPLC) | g-Aminobutyric acid benzyl ester p-tosylate 98+% (HPLC). Group: Biochemicals. Grades: Reagent Grade. Pack Sizes: 5g, 25g, 100g. US Biological Life Sciences. | Worldwide |
| g-Aminobutyric acid tert-butyl ester hydrochloride 98+% (NMR) | g-Aminobutyric acid tert-butyl ester hydrochloride 98+% (NMR). Group: Biochemicals. Grades: Reagent Grade. Pack Sizes: 250mg, 1g, 5g, 25g. US Biological Life Sciences. | Worldwide |
| Gamithromycin | Gamithromycin is a semi-synthetic macrolide derived from erythromycin. It is used to prevent and treat calf pneumonia caused by Mannheimia hemolyticus, Pasteurella multocida, Histophilus and Mycoplasma. Uses: Anti-bacterial agents. Synonyms: ML 1709460. Grade: >95% by HPLC. CAS No. 145435-72-9. Molecular formula: C40H76N2O12. Mole weight: 777.03. | |
| Gamithromycin | Gamithromycin is an antimicrobial agent which can inhibit the growth of MmmSC strains B237 and Tan8 with MICs of 0.00012 and 0.00006 μg/mL, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: ML-1709460. CAS No. 145435-72-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108365. | |
| Gamithromycin | Gamithromycin. Group: Biochemicals. Alternative Names: (2R, 3S, 4R, 5S, 8R, 10R, 11R, 12S, 13S, 14R)-13-[(2, 6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3, 4, 10-trihydroxy-3, 5, 8, 10, 12, 14-hexamethyl-7-propyl-11-[[3, 4, 6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopentadecan-15-one; ML 1709460. Grades: Highly Purified. CAS No. 145435-72-9. Pack Sizes: 1mg, 2mg, 5mg, 10mg, 25mg. Molecular Formula: C40H76N2O12. US Biological Life Sciences. | Worldwide |
| Gamithromycin | 1g Pack Size. Group: Antibiotics, Bioactive Small Molecules, Research Organics & Inorganics. Formula: C40H76N2O12. CAS No. 145435-72-9. Prepack ID 89982152-1g. Molecular Weight 777.04. See USA prepack pricing. |  |
| Gamithromycin-d4 (Major) | Isotope labelled analog of Gamithromycin (G195000), a macrolide compound which is known to have antibacterial activity, and is useful in the therapy of bacterial infections in mammals. Antibiotic. Group: Biochemicals. Alternative Names: (2R, 3S, 4R, 5S, 8R, 10R, 11R, 12S, 13S, 14R)-13-[(2, 6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3, 4, 10-trihydroxy-3, 5, 8, 10, 12, 14-hexamethyl-7-propyl-11-[[3, 4, 6-trideoxy-3-(dimethylamino)- β-D-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopentadecan-15-one; ML 1709460-d5. Grades: Highly Purified. Pack Sizes: 1mg. US Biological Life Sciences. | Worldwide |
| Gamithromycin-[d5] | Isotope labelled analog of Gamithromycin, a macrolide compound which is known to have antibacterial activity, and is useful in mammals' bacterial infections treatment. Antibiotic. Synonyms: (2R,3S,4R,5S,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopentadecan-15-one-d5; ML 1709460-d5; Gamithromycin-d5; Zactran-d5. Grade: 95%. CAS No. 2734920-04-6. Molecular formula: C40H71D5N2O12. Mole weight: 782.08. | |
| Gamitrinib TPP hexafluorophosphate | Gamitrinib TPP hexafluorophosphate is a Gamitrinib (GA) mitochondrial matrix inhibitor. Gamitrinib TPP hexafluorophosphate is a mitochondrial targeted HSP90 inhibitor with anti-cancer activity. Uses: Scientific research. Group: Signaling pathways. CAS No. 1131626-47-5. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-102007A. | |
| gamma, 10-15 nm | gamma, 10-15 nm. Group: Oxides nanoparticles. 99.99%. | |
| gamma3-MSH | gamma3-MSH. Synonyms: H-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-Arg-Arg-Asn-Gly-Ser-Ser-Ser-Ser-Gly-Val-Gly-Gly-Ala-Ala-Gln-OH; L-tyrosyl-L-valyl-L-methionyl-glycyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-L-alpha-aspartyl-L-arginyl-L-phenylalanyl-glycyl-L-arginyl-L-arginyl-L-asparagyl-glycyl-L-seryl-L-seryl-L-seryl-L-seryl-glycyl-L-valyl-glycyl-glycyl-L-alanyl-L-alanyl-L-glutamine; γ3-MSH. Grade: ≥95%. CAS No. 72629-64-2. Molecular formula: C126H188N44O37S. Mole weight: 2943.18. | |
| Gamma Aluminum Oxide | Gamma Aluminum Oxide. Group: Oxides nanoparticles. | |
| Gamma Aluminum Oxide nano powder | Gamma Aluminum Oxide nano powder. Group: Oxides nanoparticles. 99.99%. | |
| Gamma aluminum oxide spherical nanoparticles | Gamma aluminum oxide spherical nanoparticles. Group: Elements nanoparticles. >99,9%. | |
| Gamma-Aminobutyric Acid Almotriptan | A metabolite of Almotriptan. Synonyms: Almotriptan Metabolite M2. Grade: > 95%. CAS No. 603137-41-3. Molecular formula: C17H25N3O4S. Mole weight: 367.47. | |
| Gamma-Aminobutyric Acid (GABA) | Gamma-Aminobutyric Acid (GABA). |  CA, FL & NJ |
| gamma-Aminobutyric acid t-buty ester HCl | gamma-Aminobutyric acid t-buty ester HCl. Group: Biochemicals. Grades: Highly Purified. CAS No. 58640-01-0. Pack Sizes: 1g, 2g, 5g, 10g, 25g. Molecular Formula: C8H17NO2·HCl. US Biological Life Sciences. | Worldwide |
| gamma-(Aminooxy)propyl mercaptan HCl | gamma-(Aminooxy)propyl mercaptan HCl. Group: Biochemicals. Grades: Highly Purified. CAS No. 1071-99-4. Pack Sizes: 10mg, 25mg, 50mg, 100mg, 250mg. Molecular Formula: C3H10ClNOS. US Biological Life Sciences. | Worldwide |
| gamma-(BBT)-ATP | gamma-(BBT)-ATP. Group: Biochemicals. Alternative Names: gamma-[2'(2-benzothiazoyl)-6'-hydroxybenzothiazole)-adenosine-5'-triphosphate sodium salt. Grades: Highly Purified. Pack Sizes: 1mg. US Biological Life Sciences. | Worldwide |
| gamma-(BBT)-ATP | Gamma-(BBT)-ATP is a potent and selective inhibitor used in biomedicine for the treatment of various diseases. It specifically targets adenosine triphosphate (ATP) in the gamma-(BBT) pathway, offering potential therapeutic options for metabolic disorders, neurological conditions, and certain types of cancer. This product plays a critical role in accurately modulating ATP levels to restore cellular homeostasis and improve overall health. Synonyms: gamma-[2'(2-benzothiazoyl)-6'-hydroxybenzothiazole)-adenosine-5'-triphosphate sodium salt. Grade: 95%. Molecular formula: C24H22N7O13P3S2·xNa. Mole weight: 773.52 (free acid). | |
| gamma-(BBT)-GTP | gamma-(BBT)-GTP. Group: Biochemicals. Alternative Names: gamma-[2'(2-benzothiazoyl)-6'-hydroxybenzothiazole)-guanosine-5'-triphosphate sodium salt. Grades: Highly Purified. Pack Sizes: 1mg. US Biological Life Sciences. | Worldwide |
| gamma-(BBT)-GTP | gamma-(BBT)-GTP is a crucial compound in biomedicine used for studying the role of guanosine triphosphate (GTP) in cellular processes. This product plays a significant role in research related to GTP-binding proteins and signal transduction pathways. It aids in investigating diseases such as cancer, neurological disorders, and infectious diseases, thereby contributing to the development of potential therapeutics targeting GTP-related pathways. Synonyms: gamma-[2'(2-benzothiazoyl)-6'-hydroxybenzothiazole)-guanosine-5'-triphosphate sodium salt. Molecular formula: C24H22N7O14P3S2·xNa. Mole weight: 789.52 (free acid). | |
| Gamma-benzyl L-glutamate | Gamma-benzyl L-glutamate. Uses: Designed for use in research and industrial production. Additional or Alternative Names: d-glutamicacid5-benzylester;l-glutamicacid,5-(phenylmethyl)ester;GLUTAMIC ACID(OBZL)-OH;GLUTAMIC ACID-GAMMA-BENZYL ESTER;H-L-GLU(OBZL)-OH;H-L-GLU(BZL)-OH;H-GLU(OBZL)-OH;GLU(OBZL). Product Category: Heterocyclic Organic Compound. CAS No. 1676-73-9. Molecular formula: C12H15NO4. Mole weight: 237.25. Product ID: ACM1676739. Alfa Chemistry ISO 9001:2015 Certified. | |
| gamma-Butyrobetaine hydrochloride | gamma-Butyrobetaine hydrochloride. Group: Biochemicals. Alternative Names: Deoxycarnitine hydrochloride; (3-Carboxypropyl) trimethylammonium chloride. Grades: Highly Purified. CAS No. 6249-56-5. Pack Sizes: 5g. Molecular Formula: C7H16ClNO2. US Biological Life Sciences. | Worldwide |
| gamma-Butyrolactone | 100g Pack Size. Group: Aroma Chemicals, Biochemicals, Building Blocks, Flavours and Fragrance Materials. Formula: C4H6O2. CAS No. 96-48-0. Prepack ID 50639572-100g. Molecular Weight 86.09. See USA prepack pricing. | |
| gamma-Carboxyglutamic acid gamma,gamma-di-t-butyl ester | gamma-Carboxyglutamic acid gamma,gamma-di-t-butyl ester. Group: Biochemicals. Alternative Names: 3-Amino-1,1,3-propanetricarboxylic acid 1,1-bis(1,1-dimethylethyl) ester. Grades: Highly Purified. CAS No. 56877-44-2. Pack Sizes: 2mg, 5mg, 10mg, 25mg, 50mg. Molecular Formula: C14H25NO6. US Biological Life Sciences. | Worldwide |
| gamma-Carotene | gamma-Carotene. Group: Biochemicals. Grades: Highly Purified. CAS No. 472-93-5. Pack Sizes: 1mg, 2mg, 5mg. US Biological Life Sciences. | Worldwide |
Our database is helping our users find suppliers everyday.
